Elite Journal of Public Health. Volume 2 issue 3(2024), Pp. 86-99
https://epjournals.com/journals/EJPH

Neutrophil Extracellular Traps (NETs) in HIV-Induced Diarrhea: Friend or Foe?

*Emmanuel Ifeanyi Obeagu

Department of Medical Laboratory Science, Kampala International University, Uganda

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

Abstract

Neutrophil extracellular traps (NETs) represent a double-edged sword in the context of HIV-induced diarrhea, serving as both defenders and perpetrators of gut mucosal integrity. This review explores the intricate interplay between NETs and HIV-induced diarrhea, shedding light on their dual roles and potential therapeutic implications. While NETs exhibit antimicrobial properties and aid in pathogen containment, excessive or dysregulated NET formation can contribute to tissue damage, inflammation, and gut barrier dysfunction, exacerbating diarrhea severity. Targeting NET-mediated immune responses holds promise as a therapeutic strategy, with potential applications in mitigating gut mucosal damage and restoring microbial homeostasis. Furthermore, NETs and NET-associated molecules emerge as promising biomarkers for monitoring disease progression and treatment response in HIV-infected individuals with diarrhea. Understanding the complex dynamics of NETs in HIV-induced diarrhea is essential for devising effective therapeutic interventions and personalized management strategies for gastrointestinal complications in HIV-infected individuals.

Keywords: *Neutrophil extracellular traps, NETosis, HIV, Diarrhea, Gut mucosa, Immune dysregulation, Inflammation, Therapeutic targets, Biomarkers*

Introduction

HIV infection remains a significant global health challenge, with gastrointestinal complications, notably diarrhea, posing substantial burdens on affected individuals. Despite advancements in antiretroviral therapy, diarrhea remains a prevalent and distressing symptom in HIV-infected individuals, impacting their quality of life and treatment outcomes. The gastrointestinal tract serves as a major site of HIV replication and immune activation, contributing to the pathogenesis of

diarrhea through various mechanisms. Among the diverse array of immune cells involved in gut mucosal immunity, neutrophils have garnered attention for their role in orchestrating inflammatory responses and tissue damage, particularly through the formation of neutrophil extracellular traps (NETs). Neutrophil extracellular traps (NETs) represent a novel mechanism of host defense, characterized by the release of web-like structures composed of chromatin fibers, histones, and antimicrobial proteins. Originally identified as a means of entrapping and neutralizing pathogens, NETs have since been implicated in the pathogenesis of numerous inflammatory and autoimmune diseases, including HIV infection. In the context of HIV-induced diarrhea, the role of NETs is complex and multifaceted, with both protective and detrimental effects on gut mucosal integrity and immune homeostasis.[1-31]

The gut mucosa serves as a battleground where intricate interactions between HIV, host immune cells, and commensal microbes dictate disease progression and symptomatology. Neutrophils, as frontline defenders, play a crucial role in maintaining gut barrier function and combating invading pathogens. However, dysregulated neutrophil activation and excessive NET formation can contribute to tissue damage, inflammation, and gut epithelial barrier dysfunction, exacerbating diarrhea severity in HIV-infected individuals. Understanding the nuanced interplay between NETs and HIV-induced diarrhea is paramount for devising effective therapeutic interventions and personalized management strategies. Targeting NET-mediated immune responses represents a promising avenue for intervention, with potential applications in mitigating gut mucosal damage and restoring microbial homeostasis. Furthermore, elucidating the role of NETs as biomarkers may offer valuable insights into disease progression and treatment response, paving the way for precision medicine approaches in the management of gastrointestinal complications in HIV-infected individuals.[32-46]

In this review, we aim to provide a comprehensive overview of the current understanding of NETs in the context of HIV-induced diarrhea, exploring their dual roles as defenders and perpetrators of gut mucosal integrity. We will delve into the intricate mechanisms underlying NET formation, their impact on gut immune responses, and their therapeutic and diagnostic potential in managing gastrointestinal complications in HIV-infected individuals.

Neutrophil Extracellular Traps (NETs)

Neutrophil Extracellular Traps (NETs) are web-like structures composed of DNA, histones, and antimicrobial proteins that are released by activated neutrophils as a part of the innate immune response. Initially discovered as a mechanism to entrap and neutralize pathogens, NETs have since been implicated in various physiological and pathological processes. When neutrophils encounter pathogens or inflammatory stimuli, they undergo a process called NETosis, during which they release their chromatin content along with granule-derived antimicrobial proteins into the extracellular space, forming NETs. NETs play a crucial role in host defense by trapping and killing invading microorganisms, including bacteria, fungi, parasites, and viruses. They create a physical barrier that immobilizes pathogens, preventing their spread and facilitating their clearance by other immune cells. Additionally, NETs contain antimicrobial proteins such as defensins,

myeloperoxidase, and lactoferrin, which exert direct antimicrobial effects, further contributing to pathogen elimination.[47-62]

Beyond their role in host defense, NETs have been implicated in various inflammatory and autoimmune conditions. Excessive or dysregulated NET formation can lead to tissue damage and inflammation, contributing to the pathogenesis of diseases such as sepsis, rheumatoid arthritis, and inflammatory bowel disease. In addition to their antimicrobial properties, NETs can activate immune cells and promote the release of pro-inflammatory cytokines, exacerbating tissue injury and perpetuating inflammation. In the context of HIV infection, NETs have emerged as intriguing players with both protective and detrimental effects. While NETs may contribute to the containment of HIV and other opportunistic pathogens in the gut mucosa, excessive NET formation can also induce tissue damage and inflammation, exacerbating gastrointestinal complications such as diarrhea. Moreover, HIV infection itself can dysregulate neutrophil function and promote aberrant NET formation, further complicating the interplay between NETs and HIV-induced pathology.[63-72]

NETs in HIV-Induced Diarrhea

Neutrophil Extracellular Traps (NETs) have recently emerged as intriguing components in the complex pathogenesis of HIV-induced diarrhea. In the context of HIV infection, diarrhea remains a prevalent and debilitating symptom, impacting the quality of life and treatment outcomes of affected individuals. While the mechanisms underlying HIV-induced diarrhea are multifactorial, growing evidence suggests that neutrophils and their formation of NETs play a pivotal role in gut mucosal inflammation and barrier dysfunction, contributing to the pathogenesis of diarrhea. NETs are released by activated neutrophils as a response to various stimuli, including microbial pathogens, inflammatory mediators, and immune complexes. These web-like structures consist of chromatin fibers decorated with histones, antimicrobial proteins, and proteases, serving as a means of trapping and neutralizing pathogens. In the gut mucosa of HIV-infected individuals, dysregulated NET formation can lead to excessive tissue damage, inflammation, and disruption of epithelial barrier integrity, exacerbating diarrhea severity. The interplay between NETs and HIV-induced diarrhea is complex and multifaceted. On one hand, NETs may contribute to host defense by entrapping and restricting the dissemination of HIV and opportunistic pathogens within the gut mucosa. Moreover, NET-associated antimicrobial proteins exert direct bactericidal effects, potentially aiding in the clearance of invading pathogens. However, aberrant NET formation can also promote tissue damage and inflammation, exacerbating gut mucosal injury and perpetuating diarrhea. Furthermore, HIV infection itself can dysregulate neutrophil function and enhance NET formation through various mechanisms, including direct viral effects and immune activation. This dysregulation of NET formation may further exacerbate gut inflammation and barrier dysfunction, creating a vicious cycle of immune dysregulation and gastrointestinal symptoms in HIV-infected individuals.[73-96]

Therapeutic Implications

The intricate involvement of Neutrophil Extracellular Traps (NETs) in the pathogenesis of HIV-induced diarrhea offers promising therapeutic implications for managing gastrointestinal complications in HIV-infected individuals. Understanding the dual role of NETs as both defenders and perpetrators of gut mucosal integrity provides a foundation for devising targeted therapeutic interventions to alleviate symptoms and improve patient outcomes. One potential therapeutic strategy involves targeting NET formation or modulating NET-associated immune responses. Pharmacological inhibitors of NETosis, such as PAD4 inhibitors or DNase enzymes, could mitigate excessive NET formation and subsequent tissue damage in the gut mucosa. Additionally, agents that promote NET degradation, such as recombinant DNase I, may facilitate the clearance of NETs and alleviate inflammation, thereby improving diarrhea outcomes in HIV-infected individuals. Moreover, strategies aimed at restoring gut barrier integrity and microbial homeostasis may indirectly modulate NET-mediated immune responses in HIV-induced diarrhea. Probiotics and prebiotics have been shown to strengthen the gut epithelial barrier and promote beneficial microbial colonization, potentially reducing gut inflammation and NET formation in HIV-infected individuals. Furthermore, dietary interventions targeting gut microbiota composition and diversity may provide additional benefits in managing gastrointestinal symptoms associated with HIV-induced diarrhea. In addition to pharmacological interventions, immunomodulatory therapies targeting NET-associated immune responses hold promise for managing gastrointestinal complications in HIV-infected individuals. Biologics targeting specific pro-inflammatory cytokines or immune cell activation pathways implicated in NET formation could help attenuate gut inflammation and improve diarrhea outcomes. Furthermore, therapies aimed at enhancing mucosal healing and tissue repair mechanisms may mitigate the detrimental effects of NET-mediated tissue damage in the gut mucosa. Furthermore, investigating NETs as potential biomarkers may offer valuable insights into disease progression and treatment response in HIV-induced diarrhea. Quantification of circulating NET markers in plasma or stool samples could provide clinicians with valuable diagnostic and prognostic information, guiding personalized treatment strategies and improving patient care.[97-108]

Biomarker Potential

The potential of Neutrophil Extracellular Traps (NETs) as biomarkers holds significant promise in the management of HIV-induced diarrhea, offering insights into disease progression, treatment response, and personalized patient care. NETs and NET-associated molecules represent dynamic markers of gut mucosal inflammation and immune dysregulation, providing valuable diagnostic and prognostic information for clinicians. Quantification of circulating NET markers in plasma or stool samples may serve as non-invasive diagnostic tools for assessing the severity of gut inflammation and mucosal damage in HIV-infected individuals with diarrhea.[109] Elevated levels of NET-associated proteins, such as cell-free DNA, histones, and neutrophil elastase, may indicate ongoing neutrophil activation and NET formation in the gut mucosa, reflecting the extent of tissue injury and inflammation. Furthermore, longitudinal studies investigating the dynamics of NET formation and clearance could offer valuable prognostic information, guiding treatment decisions and predicting disease outcomes in HIV-induced diarrhea. Monitoring changes in circulating NET markers over time may help identify patients at increased risk of disease progression or treatment failure, allowing for timely intervention and personalized management strategies.

Citation: Obeagu EI. Neutrophil Extracellular Traps (NETs) in HIV-Induced Diarrhea: Friend or Foe? Elite Journal of Public Health, 2024; 2 (3): 86-99

Moreover, NETs may serve as pharmacodynamic biomarkers for assessing treatment response to targeted therapies aimed at modulating NET formation or enhancing NET degradation. Changes in circulating NET markers following therapeutic interventions could provide valuable insights into treatment efficacy and help optimize dosing regimens for improved clinical outcomes. In addition to their diagnostic and prognostic utility, NETs may also have predictive value in identifying individuals at risk of developing complications or comorbidities associated with HIV-induced diarrhea. Elevated levels of circulating NET markers could potentially serve as early indicators of gut mucosal damage and barrier dysfunction, prompting closer monitoring and preventive interventions to mitigate disease progression and improve long-term outcomes.[109]

Conclusion

Neutrophil Extracellular Traps (NETs) play a complex and multifaceted role in the pathogenesis of HIV-induced diarrhea. While serving as defenders by entrapping and neutralizing pathogens, excessive NET formation can lead to tissue damage, inflammation, and gut barrier dysfunction, exacerbating diarrhea severity. Therapeutic implications of targeting NET-mediated immune responses offer promising avenues for alleviating symptoms and improving outcomes in HIV-induced diarrhea. Modulating NET formation, promoting gut barrier integrity, and targeting associated immune pathways represent potential strategies for personalized patient care. Moreover, investigating NETs as biomarkers holds significant promise for diagnosing, prognosticating, and predicting treatment response in HIV-infected individuals with diarrhea.

References

1. Clay PG, Crutchley RD. Noninfectious diarrhea in HIV seropositive individuals: a review of prevalence rates, etiology, and management in the era of combination antiretroviral therapy. Infectious diseases and therapy. 2014; 3:103-122.
2. Pavlinac PB, John-Stewart GC, Naulikha JM, Onchiri FM, Denno DM, Odundo EA, Singa BO, Richardson BA, Walson JL. High-risk enteric pathogens associated with HIV infection and HIV exposure in Kenyan children with acute diarrhoea. Aids. 2014;28(15):2287-2296.
3. Shirley DA, Farr L, Watanabe K, Moonah S. A review of the global burden, new diagnostics, and current therapeutics for amebiasis. InOpen forum infectious diseases 2018 Jul (Vol. 5, No. 7, p. ofy161). US: Oxford University Press.
4. Obiako OR, Muktar HM. Challenges if HIV treatment in resource-poor countries: a review. Nigerian journal of medicine. 2010;19(4):361-368.
5. Watermeyer G, Katsidzira L, Setshedi M, Devani S, Mudombi W, Kassianides C. Inflammatory bowel disease in sub-Saharan Africa: epidemiology, risk factors, and challenges in diagnosis. The Lancet Gastroenterology & Hepatology. 2022;7(10):952-961.
6. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. Madonna University journal of Medicine and Health Sciences. 2022;2(3):120-127.
7. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023

;3(1):7-12.
https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91.

8. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. J Pub Health Nutri. 2023; 6 (2). 2023; 141:1-2. links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf.
9. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
10. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. Int J Curr Res Med Sci. 2017;3(1): 21-38.DOI: 10.22192/ijcrms.2017.03.01.004
11. Obeagu EI, Obeagu GU, Musiimenta E, Bot YS, Hassan AO. Factors contributing to low utilization of HIV counseling and testing services. Int. J. Curr. Res. Med. Sci. 2023;9(2): 1-5.DOI: 10.22192/ijcrms.2023.09.02.001
12. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;129. links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf.
13. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.
14. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
15. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. Journal of Pharmaceutical Research International. 2020;32(22):101-119.
16. Obeagu EI, Eze VU, Alaeboh EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. J BioInnovation. 2016; 5:464-471. links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf.
17. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. International Journal of Current Microbiology and Applied Sciences. 2015;4(4):911-916.
https://www.academia.edu/download/38320140/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma2.EMMA1.pdf.
18. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. Int. J. Adv. Res. Biol. Sci. 2016;3(10): 55-65.DOI; 10.22192/ijarbs.2016.03.10.009

19. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75. links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf
20. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. Madonna University journal of Medicine and Health Sciences. 2022;2(3):110-119.
21. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. J. Bio. Innov. 2016;5(1):24-30. links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf.
22. Igwe CM, Obeagu IE, Ogbuabor OA. Clinical characteristics of people living with HIV/AIDS on ART in 2014 at tertiary health institutions in Enugu, Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;130. links/645a166f5762c95ac3817d32/Clinical-characteristics-of-people-living-with-HIV-AIDS-on-ART-in-2014-at-tertiary-health-institutions-in-Enugu.pdf.
23. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. Int J Curr Res Aca Rev. 2015; 3:139-144. https://www.academia.edu/download/38320159/Obeagu_Emmanuel_Ifeanyi3__et_al.IJCRAR.pdf.
24. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. Ann Clin Lab Res. 2018;6(1):1-4. links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf
25. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. Int. J. Curr. Res. Med. Sci. 2017;3(2): 28-34.DOI: 10.22192/ijcrms.2017.03.02.005
26. Esimai BN, Obeagu EI. Prevalence of Isolated Agent in Diarrheal Infections of Children O-3 Years in Anambra State in Relation to Sex: A Survey of Five Rural Communities. J Biomed Sci. 2022;11(8):73. links/630c87eb1ddd447021194fca/Prevalence-of-Isolated-Agent-in-Diarrheal-Infections-of-Children-O-3-Years-in-Anambra-State-in-Relation-to-Sex-A-Survey-of-Five-Rural-Communities.pdf.
27. Ezimah UA, Obeagu EI, Ezimah CO, Ezimah A, Nto NJ. Diarrhoeal diseases of acquired immunodeficiency syndrome stimulate more depletion of total antioxidant status. Int. J. Adv. Multidiscip. Res. 2016;3(4):23-5. links/592bb593aca27295a80b964c/International-Journal-of-Advanced-Multidisciplinary-Research-IJAMR-Diarrhoeal-diseases-of-

acquired-immunodeficiency-syndrome-stimulate-more-depletion-of-total-antioxidant-status.pdf.

28. Ojo BO, Abdulrahman OA, Haassan AO, Obeagu EI, Olamijuwon PB, Oyeromi BO, Oluwanisola DO, Kelvin U. Plasmid Profiling of Bacteria Associated with Gastroenteritis among Children in Owo, Ondo State. Asian Journal of Research and Reports in Gastroenterology. 2022 Jul 26;6(2):29-41.
29. Obeagu GU, Obeagu EI. Diarrhoea disease: A dangerous childhood disease. CPQ Women Child Health. 2019;1(6):01-8.
30. Ogbu IS, Okafor EO, Obeagu EI, Ogbu CC, Esimai BN, Okeke NJ, Ukeekwe CO. Effect of Oral Administration of the Leaf Extract of Uvaria chamae (Mmimi Ohia) in Albino Wistar Rats. Journal of Pharmaceutical Research International. 2020 Oct 6;32(24):52-6.
31. Obeagu EI, Obeagu GU, Habimana JB. Iron Deficiency Anaemia in Children. International Research in Medical and Health Sciences. 2023 Sep 11;6(4):26-32.
32. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Science Reports. 2023;6(8):e1450.
33. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. J Pub Health Nutri. 2023; 6 (1). 2023;139. links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf.
34. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. Madonna University journal of Medicine and Health Sciences. 2022;2(3):128-134. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86.
35. Walter O, Anaebo QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. Journal of Pharmaceutical Research International. 2022:29-34.
36. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. Journal of Pharmaceutical Research International. 2020;32(24):9-18.
37. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. J Pub Health Nutri. 2022; 5 (8). 2022;137. links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf.
38. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. Int. J. Adv. Res. Biol. Sci. 2023;10(9):135-142.DOI: 10.22192/ijarbs.2023.10.09.015 links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf

39. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. Int. J. Adv. Res. Biol. Sci. 2023;10(9):128-134.DOI: 10.22192/ijarbs.2023.10.09.014 links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf.
40. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfected with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2017;3(5):100-104.DOI: 10.22192/ijcrms.2017.03.05.014 https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfected_with_HIV.pdf
41. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. South Asian Journal of Research in Microbiology. 2022;13(2):26-31.
42. Ifeanyi OE, Chibunna OM, Braxton NA, Uche EC. Impact of Plasmodium falciparum malaria and hookworm infection on anaemia among pregnant women of ikwuano local government area, Abia state, Nigeria. Int J Curr Microbiol Appl Sci. 2014;3(1):104-1.
43. Ifeanyi OE. A review on free radicals and antioxidants. Int. J. Curr. Res. Med. Sci. 2018;4(2):123-33.DOI: 10.22192/ijcrms.2018.04.02.019
44. Nwandkor UU, Ifeanyi OE. Bacteriological assessment of different borehole drinking water sources in Umuahia Metropolis. International Journal of Current Microbiology and Applied Sciences. 2015;4(5):1139-50. links/5712132008ae39beb87a2ee4/Bacteriological-Assessment-of-Different-Borehole-Drinking-Water-Sources-in-Umuahia-Metropolis.pdf.
45. Stella EI, Ifeanyi OE. A review on salmonella species and indicator organisms in drinking water. Int J Compr Res Biol Sci. 2018;5(2):5-23. *DOI: http://dx.doi.org/10.22192/ijcrbs.2018.05.02.002*
46. Ugwuzor NU, Ifeanyi OE, Onyenweaku FC. Bacteriolcgical Assessment of Stream Drinking Water from various Sources in Umuahia Metropolis. World Journal of Pharmaceutical Research. 2015 Mar 19;4(6):122-37.
47. Yang H, Biermann MH, Brauner JM, Liu Y, Zhao Y, Herrmann M. New insights into neutrophil extracellular traps: mechanisms of formation and role in inflammation. Frontiers in immunology. 2016; 7:207281.
48. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. J Clin Commun Med. 2020;2(3):180-183.DOI: **DOI:** 10.32474/JCCM.2020.02.000137 links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ElISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf.
49. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. Journal of Pharmaceutical Research International. 2021;33(47A):78-84.

50. Emannuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. Asian Journal of Pregnancy and Childbirth. 2023 Jul 29;6(1):203-211. http://research.sdpublishers.net/id/eprint/2819/.
51. Igwe MC, Obeagu EI, Ogbuabor AO, Eze GC, Ikpenwa JN, Eze-Steven PE. Socio-Demographic Variables of People Living with HIV/AIDS Initiated on ART in 2014 at Tertiary Health Institution in Enugu State. Asian Journal of Research in Infectious Diseases. 2022;10(4):1-7.
52. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. Journal of Pharmaceutical Research International. 2021;33(57A):360-368.
53. Igwe MC, Obeagu EI, Ogbuabor AO. Analysis of the Factors and Predictors of Adherence to Healthcare of People Living With Hiv/Aids In Tertiary Health Institutions In Enugu State. Madonna University Journal of Medicine and Health Sciences. 2022;2(3):42-57. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/75.
54. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. Madonna University journal of Medicine and Health Sciences. 2022;2(3):6-15. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69
55. Echendu GE, Vincent CC, Ibebuike J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. European Journal of Pharmaceutical and Medical Research, 2023; 10(8): 564-568
56. Nwosu DC, Nwanjo HU, Okolie NJ, Ikeh K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatunanya I, Azuonwu O. BIOCHEMICAL ALTERATIONS IN ADULT HIV PATIENTS ON ANTIRETRQVIRAL THERAPY. World Journal of Pharmacy and Pharmaceutical Sciences, 2015; 4(3): 153-160**.** links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETRQVIRAL-THERAPY.pdf.
57. Obeagu EI, Obeagu GU. Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. Int. J. Curr. Res. Biosci. Plant Biol. 2015;2(4):45-49.
58. Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active antiretro viral therapy: a review of prevalence. Int. J. Curr. Res. Chem. Pharm. Sci. 2019;6(12):45-8.DOI: 10.22192/ijcrcps.2019.06.12.004 links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf.
59. Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. Int. J. Curr. Res. Med. Sci. 2023;9(2):6-13.DOI: 10.22192/ijcrms.2023.09.02.002 links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf.
60. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. Int. J. Curr. Res. Med. Sci.

2016;2(4):29-33. links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf.

61. Ifeanyi OE, Obeagu GU. The Values of CD4 Count, among HIV Positive Patients in FMC Owerri. Int. J. Curr. Microbiol. App. Sci. 2015;4(4):906-910. https://www.academia.edu/download/38320134/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma.EMMA2.pdf.
62. Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. Int. J. Curr. Res. Biol. Med. 2016;1(2):1-5.
63. Ibebuike JE, Nwokike GI, Nwosu DC, Obeagu EI. A Retrospective Study on Human Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo State University Teaching Hospital. *International Journal of Medical Science and Dental Research,* 2018; 1 (2):08-14. https://www.ijmsdr.org/published%20paper/li1i2/A%20Retrospective%20Study%20on%20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%20Attending%20Antenatal%20Clinic%20in%20Imo%20State%20University%20Teaching%20Hospital.pdf.
64. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some haematological and biochemical parametrs in HIV patients before receiving treatment in Aba, Abia State, Nigeria. Res J Pharma Biol Chem Sci. 2014; 5:825-830.
65. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebo QB, Eze GC. Pattern of total white blood cell and differential count values in HIV positive patients receiving treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. International Journal of Life Science, Biotechnology and Pharama Research. 2014; 391:186-189.
66. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023; 3 (1): 7-12.
67. Oloro OH, Obeagu EI. A Systematic Review on Some Coagulation Profile in HIV Infection. International Journal of Innovative and Applied Research. 2022;10(5):1-11.
68. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Ezemma MC, Okpomeshine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutiase, vitamins C and E in HIV infected children in Umuahia, Abia state. International Journal of Advanced Research in Biological Sciences. 2015;2(11):268-271.
69. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC. Vitamin D and insulin resistance in HIV sero positive individuals in Umudike. Int. J. Curr. Res. Med. Sci. 2018;4(2):104-108.
70. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK. A Review on blood borne viral infections: universal precautions. Int. J. Adv. Res. Biol. Sci. 2018;5(6):60-66.
71. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. Arch Blood Transfus Disord. 2018;1(2).
72. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75.

73. Obeagu EI. Effects of Long-Term Omeprazole Use on Red Blood Cells: A Review. Elite Journal of Medica Science. 2024;2(1):44-52.
74. Onyeaghala EO, Maxwel EA, Obeagu EI, Hassan AO. Assessment of the Problems Associated with the use of Public Latrine System in Ife-North Local Government, Osun State, Nigeria. RESEARCH IN MEDICAL SCIENCES (NIJRMS). 2024;5(1).
75. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.
76. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA. Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A review. Medicine (Baltimore). 2023;102(49): e36599. doi: 10.1097/MD.0000000000036599. PMID: 38065920; PMCID: PMC10713174.
77. Anyiam AF, Arinze-Anyiam OC, Irondi EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. Medicine (Baltimore). 2023;102(47): e36342. doi: 10.1097/MD.0000000000036342. PMID: 38013335; PMCID: PMC10681551.
78. Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria. Medicine (Baltimore). 2023;102(47): e35910. doi: 10.1097/MD.0000000000035910. PMID: 38013350; PMCID: PMC10681510.
79. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. Medicine (Baltimore). 2023;102(46): e36166. doi: 10.1097/MD.0000000000036166. PMID: 37986340; PMCID: PMC10659731.
80. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR,
81. Obeagu EI, Ubosi NI, Uzoma G. Storms and Struggles: Managing HIV Amid Natural Disasters. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(11):14-25.
82. Obeagu EI, Obeagu GU. Human Immunodeficiency Virus and tuberculosis infection: A review of prevalence of associated factors. Int. J. Adv. Multidiscip. Res. 2023;10(10):56-62.
83. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sickle Cell Anaemia. Newport International Journal of Scientific and Experimental Sciences (NIJSES). 2023;3(2):56-9.
84. Obeagu EI, Obeagu GU. Unmasking the Truth: Addressing Stigma in the Fight Against HIV. Elite Journal of Public Health. 2024;2(1):8-22.
85. Obeagu EI, Obeagu GU, Okwuanaso CB. Optimizing Immune Health in HIV Patients through Nutrition: A Review. Elite Journal of Immunology. 2024;2(1):14-33.
86. Obeagu EI, Obeagu GU. Utilization of immunological ratios in HIV: Implications for monitoring and therapeutic strategies. Medicine. 2024;103(9): e37354.
87. Obeagu EI, Obeagu GU. CD8 Dynamics in HIV Infection: A Synoptic Review. Elite Journal of Immunology. 2024;2(1):1-3.

88. Obeagu EI, Obeagu GU. Implications of B Lymphocyte Dysfunction in HIV/AIDS. Elite Journal of Immunology. 2024;2(1):34-46.
89. Obeagu EI, Obeagu GU. Maternal Influence on Infant Immunological Responses to HIV: A Review. Elite Journal of Laboratory Medicine. 2024;2(1):46-58.
90. Obeagu EI, Obeagu GU. Understanding B Lymphocyte Functions in HIV Infection: Implications for Immune Dysfunction and Therapeutic Strategies. Elite Journal of Medicine. 2024;2(1):35-46.
91. Obeagu EI, Obeagu GU. Platelet-Driven Modulation of HIV: Unraveling Interactions and Implications. Journal home page: http://www. journalijiar. com.;12(01).
92. Obeagu EI, Anyiam AF, Obeagu GU. Managing Hematological Complications in HIV: Erythropoietin Considerations. Elite Journal of HIV. 2024;2(1):65-78.
93. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Hematocrit Variations in HIV Patients Co-infected with Malaria: A Comprehensive Review. Journal home page: http://www. journalijiar. com.;12(01).
94. ObeaguEI AA, Obeagu GU. Synergistic Effects of Blood Transfusion and HIV in Children Under 5 Years with Severe Malaria: A Review. Elite Journal of HIV. 2024;2(1):31-50.
95. Obeagu EI, Anyiam AF, Obeagu GU. Unveiling B Cell Mediated Immunity in HIV Infection: Insights, Challenges, and Potential Therapeutic Avenues. Elite Journal of HIV. 2024;2(1):1-5.
96. Obeagu EI, Obeagu GU. Hematocrit Fluctuations in HIV Patients Co-infected with Malaria Parasites: A Comprehensive Review. Int. J. Curr. Res. Med. Sci. 2024;10(1):25-36.
97. Cheah IK, Halliwell B. Could ergothioneine aid in the treatment of coronavirus patients? Antioxidants. 2020;9(7):595.
98. Obeagu EI, Obeagu GU. Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes. Sciences. 2024;4(1):32-7.
99. Obeagu EI, Obeagu GU. Mental Health and Psychosocial Effects of natural disaster on HIV Patients. Sciences. 2024;4(1):38-44.
100. Obeagu EI, Obeagu GU. Eosinophil-Associated Changes in Neonatal Thymic T Regulatory Cell Populations in HIV-Infected Pregnancies. Elite Journal of Health Science. 2024;2(1):33-42.
101. Obeagu EI, Obeagu GU. Advances in Understanding the Impact of Blood Transfusion on Anemia Resolution in HIV-Positive Children with Severe Malaria: A Comprehensive Review. Elite Journal of Haematology. 2024;2(1):26-41.
102. Obeagu EI, Ayogu EE, Obeagu GU. Interactions between Blood Transfusion and Antiretroviral Medications: Implications for Patient Care. Elite Journal of Medicine. 2024;2(2):104-15.
103. Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. Elite Journal of Immunology. 2024;2(1):47-64.
104. Obeagu EI, Anyanwu CN, Obeagu GU. Challenges and Considerations in Managing Blood Transfusion for Individuals with HIV. Elite Journal of HIV. 2024;2(2):1-7.
105. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. Elite Journal of Public Health. 2024;2(1):52-61.

106. Obeagu EI, Obeagu GU. Understanding Hematocrit Fluctuations in HIV-Malaria Coinfection for Improved Management. Elite Journal of Public Health. 2024;2(1):22-34.
107. Obeagu EI, Obeagu GU. The Impact of Erythropoietin on Preeclampsia in HIV-Positive Women: A Review. Elite Journal of Nursing and Health Science. 2024;2(1):21-31.
108. Obeagu EI, Obeagu GU. Platelet Distribution Width (PDW) as a Prognostic Marker for Anemia Severity in HIV Patients: A Comprehensive Review. Journal home page: http://www. journalijiar. com.;12(01).
109. Serrano-Villar S, Talavera-Rodríguez A, Gosalbes MJ, Madrid N, Pérez-Molina JA, Elliott RJ, Navia B, Lanza VF, Vallejo A, Osman M, Dronda F. Fecal microbiota transplantation in HIV: A pilot placebo-controlled study. Nature Communications. 2021;12(1):1139.